Receive The Newest Study Notifications

 ReGenTree, LLC (the Company), a joint venture company between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it initiated a randomized, double masked, placebo-controlled Phase 3 clinical trial (ARISE-3) for dry eye syndrome on May 10. The objective of the...

CRF Bracket, a leading patient-centric clinical technology company, has increased its strategic investment in the Asia-Pacific Region with the opening of a new office in Tokyo, Japan. A ribbon cutting ceremony was held on 8 May in the Roppongi district of the city,...

Polarean Imaging PLC on Monday said that it is progressing on its phase III clinical trials and plans to add an extra site in its lung resection pathway trial to improve the rate of enrollment. The company is carrying out two trials at Duke University and at the...

Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced progress toward the opening of Roswell Park Comprehensive...

ClinOne is pleased to announce that Dr. Elizabeth Esterl joins ClinOne as our VP of Operations and Research. Dr. Esterl brings with her a depth and breadth of knowledge in clinical trials spanning her 20+ year career in research, including over 13 years at Children’s...

The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) and the...

Vyome Therapeutics, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today presented positive results from two clinical trials testing its lead anti-acne candidate, VB-1953, at the...

The number of clinical trials involving medicines and medical devices is on the increase in Ireland, a national seminar has been told. Currently in Ireland, there are 423 clinical trials offering patient access to innovative therapies, excluding cancer trials...

CytoDyn Inc. a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announces an agreement with The Cleveland Clinic’s Dr. Daniel Lindner, M.D., Ph.D. to test leronlimab’s ability...

BioCryst Pharmaceuticals, Inc. (BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers.  In the trial, galidesivir was generally safe and well tolerated. This...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer's Clinical Trials Consortium (ACTC) and BioArctic's partner Eisai have announced the selection of BAN2401 to be evaluated in an upcoming clinical study targeting secondary prevention of...

Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating safety, tolerability, and...

EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the first four patients have been dosed in a Phase 1/2a study using the Company's...

Cerveau Technologies Inc.,today announced a research collaboration with the LuMind IDSC Foundation (LuMind IDSC) involving use of Cerveau’s investigational imaging agent (MK-6240) in a multicenter clinical trial aimed at assessing accumulation of misfolded tau protein...

A new therapy to re-engage the heart’s natural electrical pathways – instead of bypassing them – could mean more treatment options for heart failure patients who also suffer from electrical disturbances, such as arrhythmias, according to research led by the University...

LATITUDE study compares monthly injectable antiretroviral therapy to daily oral drugs A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge...

Plain language trial summary template for patients will be available to all members in the National Cancer Institute’s National Clinical Trials Network. With financial support from The Hope Foundation for Cancer Research, a team of patient advocates and communications...

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today...

 Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries (“TBIs”), both concussions and penetrating injuries,...

Many forget to take daily pills, experimental injectable drugs last longer Researchers at the University of Colorado Anschutz Medical Campus, working with the National Institutes of Health, will conduct a clinical trial beginning this month to determine if monthly...